Contrasting TC Biopharm (NASDAQ:TCBP) & Moderna (NASDAQ:MRNA)

Moderna (NASDAQ:MRNA) and TC Biopharm (NASDAQ:TCBP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Institutional & Insider Ownership

75.3% of Moderna shares are owned by institutional investors. Comparatively, 16.3% of TC Biopharm shares are owned by institutional investors. 15.7% of Moderna shares are owned by company insiders. Comparatively, 15.4% of TC Biopharm shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Moderna and TC Biopharm, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	2	14	4	0	2.10
TC Biopharm	0	0	0	0	N/A

Moderna presently has a consensus target price of $94.65, indicating a potential upside of 74.11%. Given Moderna’s higher possible upside, research analysts plainly believe Moderna is more favorable than TC Biopharm.

Valuation & Earnings

This table compares Moderna and TC Biopharm”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$4.99 billion	4.18	-$4.71 billion	($15.67)	-3.47
TC Biopharm	$4.76 million	0.15	-$7.35 million	N/A	N/A

TC Biopharm has lower revenue, but higher earnings than Moderna.

Profitability

This table compares Moderna and TC Biopharm’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-116.18%	-21.35%	-15.75%
TC Biopharm	N/A	N/A	N/A

Risk & Volatility

Moderna has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.

Summary

Moderna beats TC Biopharm on 7 of the 11 factors compared between the two stocks.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.